Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.

"Conflict of Interest Statement Philippe Merle has received consulting fees from Bayer, Ipsen, Eli Lilly, Eisai, Roche, AstraZeneca, Bristol-Myers Squibb, and Roche; travel expenses from Bayer, Ipsen, Roche, and Bristol-Myers Squibb; and research funding (to institution) from Ipsen. Masatoshi Kudo has received grants from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, EA Pharma, Ono Pharma, Gilead Sciences, and AbbVie; lecturing fees from Bayer, Eisai, MSD, BMS, EA Pharma, Eli Lilly, Chugai, and Ajinomoto; advisory and consultancy fees from Bayer, Eisai, Ono, Kowa, MSD, BMS, Roche, Chugai, and Taiho. Masatoshi Kudo is Editor-in-Chief of Liver Cancer. Stanimira Krotneva and Irina Proskorovsky are employed by Evidera. Kirhan Ozgurdal and Yun Su are employed by Bayer."

"This study was funded by Bayer. The authors employed by the sponsors were involved in the study's design, data interpretation, and preparation of the manuscript."